Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bioray Lab Starts Tests of Gene Edited PD1-Knockin CAR-T Candidate

publication date: Sep 28, 2020

Bioray Laboratories of Shanghai reported positive initial results from a test of its gene-edited CAR-T therapy. The company uses gene editing to form a PD1-knockin CAR-T molecule, which it has administered to patients with relapsed/refractory B-cell non-Hodgkin lymphoma. The non-viral PD1 specific targeted CAR-T therapy is constructed by inserting a CAR cassette into a PD1 locus without using a virus, generating the CAR-T product in one step. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital